GTx-758

GTx-758
Clinical data
Other names	Capesaris
Routes of; administration	By mouth
Legal status
Legal status	US: Investigational New Drug;
Identifiers
	IUPAC name 3-fluoro-N-(4-fluorophenyl)-4-hydroxy-N-(4-hydroxyphenyl)benzamide;
CAS Number	938067-78-8;
PubChem CID	46861578;
ChemSpider	34954411;
UNII	406GR1485Z;
ChEMBL	ChEMBL3545017;
CompTox Dashboard (EPA)	DTXSID401045796 ;
Chemical and physical data
Formula	C19H13F2NO3
Molar mass	341.314 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC(=CC=C1N(C2=CC=C(C=C2)F)C(=O)C3=CC(=C(C=C3)O)F)O;
	InChI InChI=1S/C19H13F2NO3/c20-13-2-4-14(5-3-13)22(15-6-8-16(23)9-7-15)19(25)12-1-10-18(24)17(21)11-12/h1-11,23-24H; Key:FBCQEUMZZNVQKD-UHFFFAOYSA-N;

GTx-758 (tentative brand name Capesaris) is a synthetic nonsteroidal estrogen which was under development by GTx, Inc. for the treatment of advanced prostate cancer.^[1] As of 2016, it had completed two phase II clinical trials.^[2]

^ Coss CC, Jones A, Parke DN, Narayanan R, Barrett CM, Kearbey JD, et al. (March 2012). "Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancer". Endocrinology. 153 (3): 1070–1081. doi:10.1210/en.2011-1608. PMID 22294742.
^ "GTX 758". AdisInsight. Springer Nature Switzerland AG.

Clinical data

Other names	Capesaris
Routes of administration	By mouth
Legal status
Legal status	US: Investigational New Drug
Identifiers
IUPAC name 3-fluoro-N-(4-fluorophenyl)-4-hydroxy-N-(4-hydroxyphenyl)benzamide
CAS Number	938067-78-8
PubChem CID	46861578
ChemSpider	34954411
UNII	406GR1485Z
ChEMBL	ChEMBL3545017
CompTox Dashboard (EPA)	DTXSID401045796
Chemical and physical data
Formula	C₁₉H₁₃F₂NO₃
Molar mass	341.314 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C1=CC(=CC=C1N(C2=CC=C(C=C2)F)C(=O)C3=CC(=C(C=C3)O)F)O
InChI InChI=1S/C19H13F2NO3/c20-13-2-4-14(5-3-13)22(15-6-8-16(23)9-7-15)19(25)12-1-10-18(24)17(21)11-12/h1-11,23-24H Key:FBCQEUMZZNVQKD-UHFFFAOYSA-N